{"context":{"query":">>mondo>>clinical_trials","source_dataset":"mondo","target_dataset":"clinical_trials"},"stats":{"queried":1,"total":100,"mapped":1},"pagination":{"has_next":true,"next_token":"-1[]MONDO:0018975,73,MONDO:0018975,177,-1]["},"schema":"id|brief_title|overall_status|phase|study_type","mappings":[{"input":"MONDO:0018975","source":"MONDO:0018975|neurofibromatosis type 1","targets":["NCT00169611|NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate|COMPLETED|PHASE4|INTERVENTIONAL","NCT03975829|Pediatric Long-Term Follow-up and Rollover Study|ACTIVE_NOT_RECRUITING|PHASE4|INTERVENTIONAL","NCT02256124|Effect of Lamotrigine on Cognition in NF1|TERMINATED|PHASE2/PHASE3|INTERVENTIONAL","NCT02471339|Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain|COMPLETED|PHASE3|INTERVENTIONAL","NCT03871257|A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT04461886|A Long-term Study of NPC-12G Gel in Neurofibromatosis Type I|TERMINATED|PHASE3|INTERVENTIONAL","NCT04924608|Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT05913037|FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT00021541|R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas|COMPLETED|PHASE2|INTERVENTIONAL","NCT00030264|Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas|COMPLETED|PHASE2|INTERVENTIONAL","NCT00076102|Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas|COMPLETED|PHASE2|INTERVENTIONAL","NCT00304083|Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors|COMPLETED|PHASE2|INTERVENTIONAL","NCT00326872|AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine|TERMINATED|PHASE2|INTERVENTIONAL","NCT00589784|Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma|COMPLETED|PHASE2|INTERVENTIONAL","NCT00634270|A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas|COMPLETED|PHASE2|INTERVENTIONAL","NCT00754780|Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1|COMPLETED|PHASE2|INTERVENTIONAL","NCT00846430|Medical Treatment of High-Risk Neurofibromas|COMPLETED|PHASE2|INTERVENTIONAL","NCT00853580|A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1|COMPLETED|PHASE2|INTERVENTIONAL","NCT01089101|Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma|ACTIVE_NOT_RECRUITING|PHASE1/PHASE2|INTERVENTIONAL","NCT01125046|Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas|COMPLETED|PHASE2|INTERVENTIONAL","NCT01140360|Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT01362803|AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors|ACTIVE_NOT_RECRUITING|PHASE1/PHASE2|INTERVENTIONAL","NCT01402817|Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas|TERMINATED|PHASE2|INTERVENTIONAL","NCT01412892|Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas|COMPLETED|PHASE2|INTERVENTIONAL","NCT01553149|Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma|COMPLETED|PHASE2|INTERVENTIONAL","NCT01673009|Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas|COMPLETED|PHASE2|INTERVENTIONAL","NCT01968590|Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1)|TERMINATED|PHASE2|INTERVENTIONAL","NCT02096471|MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1|COMPLETED|PHASE2|INTERVENTIONAL","NCT02101736|Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults|COMPLETED|PHASE2|INTERVENTIONAL","NCT02332902|Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T|COMPLETED|PHASE2|INTERVENTIONAL","NCT02407405|MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas|ACTIVE_NOT_RECRUITING|PHASE2|INTERVENTIONAL","NCT02728388|Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II|RECRUITING|PHASE2|INTERVENTIONAL","NCT02839720|Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma|COMPLETED|PHASE2|INTERVENTIONAL","NCT02964884|Interventions for Reading Disabilities in NF1|ACTIVE_NOT_RECRUITING|PHASE2|INTERVENTIONAL","NCT03090971|Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1|COMPLETED|PHASE2|INTERVENTIONAL","NCT03109301|Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)|WITHDRAWN|PHASE2|INTERVENTIONAL","NCT03190915|Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia|ACTIVE_NOT_RECRUITING|PHASE2|INTERVENTIONAL","NCT03231306|Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas|COMPLETED|PHASE2|INTERVENTIONAL","NCT03326388|Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT03433183|SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors|COMPLETED|PHASE2|INTERVENTIONAL","NCT03741101|Treatment of NF1-related Plexiform Neurofibroma With Trametinib|ACTIVE_NOT_RECRUITING|PHASE2|INTERVENTIONAL","NCT03962543|MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas|ACTIVE_NOT_RECRUITING|PHASE2|INTERVENTIONAL","NCT04435665|NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)|COMPLETED|PHASE2|INTERVENTIONAL","NCT04481035|Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1|COMPLETED|PHASE2|INTERVENTIONAL","NCT04481048|Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1|ACTIVE_NOT_RECRUITING|PHASE2|INTERVENTIONAL","NCT04544007|A Phase II Trial of Poly-ICLC for Low-Grade Gliomas|TERMINATED|PHASE2|INTERVENTIONAL","NCT04750928|Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas|RECRUITING|PHASE1/PHASE2|INTERVENTIONAL","NCT04954001|Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1|ACTIVE_NOT_RECRUITING|PHASE1/PHASE2|INTERVENTIONAL","NCT05005845|NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)|COMPLETED|PHASE2|INTERVENTIONAL","NCT05253131|Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas|NOT_YET_RECRUITING|PHASE2|INTERVENTIONAL","NCT05309668|Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN|ACTIVE_NOT_RECRUITING|PHASE1/PHASE2|INTERVENTIONAL","NCT05331105|HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas|RECRUITING|PHASE2|INTERVENTIONAL","NCT05735717|MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies|RECRUITING|PHASE2|INTERVENTIONAL","NCT05825365|Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled Study|WITHDRAWN|PHASE2|INTERVENTIONAL","NCT05849662|A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia|RECRUITING|PHASE1/PHASE2|INTERVENTIONAL","NCT06159166|Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).|RECRUITING|PHASE1/PHASE2|INTERVENTIONAL","NCT06188741|Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1|RECRUITING|PHASE2|INTERVENTIONAL","NCT06541847|A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1|RECRUITING|PHASE2|INTERVENTIONAL","NCT06620354|Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule|NOT_YET_RECRUITING|PHASE2|INTERVENTIONAL","NCT06621082|The Clinical Study of the Treatment of Patients With Type I Neurofibromatosis With Smetinib Hydrosulfate Capsule|NOT_YET_RECRUITING|PHASE2|INTERVENTIONAL","NCT06735820|Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST|NOT_YET_RECRUITING|PHASE1/PHASE2|INTERVENTIONAL","NCT07024394|Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1|NOT_YET_RECRUITING|PHASE1/PHASE2|INTERVENTIONAL","NCT00053937|Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas|COMPLETED|PHASE1|INTERVENTIONAL","NCT00352495|Vinblastine and Carboplatin in Treating Young Patients With Newly Diagnosed or Recurrent Low-Grade Glioma|COMPLETED|PHASE1|INTERVENTIONAL","NCT00352599|Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1)|COMPLETED|PHASE1|INTERVENTIONAL","NCT00657202|Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1|COMPLETED|EARLY_PHASE1|INTERVENTIONAL","NCT00727233|Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas|COMPLETED|PHASE1|INTERVENTIONAL","NCT00865644|Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1|COMPLETED|PHASE1|INTERVENTIONAL","NCT01275586|Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas|COMPLETED|EARLY_PHASE1|INTERVENTIONAL","NCT01633008|Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain|COMPLETED|EARLY_PHASE1|INTERVENTIONAL","NCT02211768|Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1|COMPLETED|PHASE1|INTERVENTIONAL","NCT02415153|Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors|COMPLETED|PHASE1|INTERVENTIONAL","NCT02700230|Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery|COMPLETED|PHASE1|INTERVENTIONAL","NCT03649165|A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants|COMPLETED|PHASE1|INTERVENTIONAL","NCT04495127|Selumetinib Paediatric NF1 Japan Study|COMPLETED|PHASE1|INTERVENTIONAL","NCT04590235|A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)|ACTIVE_NOT_RECRUITING|PHASE1|INTERVENTIONAL","NCT05101148|Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas|ACTIVE_NOT_RECRUITING|PHASE1|INTERVENTIONAL","NCT05363267|NF-1, Nutraceutical Intervention|ACTIVE_NOT_RECRUITING|PHASE1|INTERVENTIONAL","NCT06104488|A Study of Avutometinib for People With Solid Tumor Cancers|RECRUITING|PHASE1|INTERVENTIONAL","NCT06120036|Dosing and Tolerability of Deoxycholic Acid vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas|COMPLETED|PHASE1|INTERVENTIONAL","NCT06132165|Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas|COMPLETED|PHASE1|INTERVENTIONAL","NCT06300502|Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs)|ENROLLING_BY_INVITATION|PHASE1|INTERVENTIONAL","NCT06502171|Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas|NOT_YET_RECRUITING|PHASE1|INTERVENTIONAL","NCT06934928|Assessing the Efficacy of Repeat, Monthly Treatments of Alexandrite Laser for NF1-associated Cutaneous Neurofibromas (cNFs)|NOT_YET_RECRUITING|PHASE1|INTERVENTIONAL","NCT06961565|PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas|RECRUITING|PHASE1|INTERVENTIONAL","NCT07102394|Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1|RECRUITING|PHASE1|INTERVENTIONAL","NCT00006435|Study of Plexiform Neurofibromas in Neurofibromatosis Type 1|COMPLETED|nan|OBSERVATIONAL","NCT00026780|Eligibility Screening for a NCI Pediatric Oncology Branch Research Study|COMPLETED|nan|OBSERVATIONAL","NCT00060008|Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma|TERMINATED|nan|INTERVENTIONAL","NCT00111384|Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1)|COMPLETED|nan|OBSERVATIONAL","NCT00303368|Neurofibromatosis Type 1 (NF1) and Tibial Dysplasia|COMPLETED|nan|OBSERVATIONAL","NCT00314119|Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1|COMPLETED|nan|OBSERVATIONAL","NCT00508235|Quality of Friendships in Children With Neurofibromatosis|COMPLETED|nan|OBSERVATIONAL","NCT00598351|Natural History Study of Patients With Neurofibromatosis Type 2|RECRUITING|nan|OBSERVATIONAL","NCT00624234|Neurobiology and Treatment of Reading Disability in NF-1|COMPLETED|nan|INTERVENTIONAL","NCT00667836|Multi-center Project: Spinal Abnormalities in Neurofibromatosis Type1 (NF1) Patients|COMPLETED|nan|OBSERVATIONAL","NCT00684398|Adaptation and Quality of Life Among Adults With Neurofibromatosis Type I|COMPLETED|nan|OBSERVATIONAL","NCT00844129|Spinal Abnormalities in Neurofibromatosis Type 1 (NF1)|COMPLETED|nan|OBSERVATIONAL","NCT00924196|Natural History Study of Patients With Neurofibromatosis Type I|ACTIVE_NOT_RECRUITING|nan|OBSERVATIONAL","NCT01058330|Effects of Physical Training on Bone and Muscle Quality, Muscle Strength, and Motor Coordination in Children With NF1|COMPLETED|nan|INTERVENTIONAL"]}]}